OBJECTIVE: Povidone-iodine (PVP-I) or Betadine, owing to its antineoplastic activity, is also used as an adjuvant during intra-abdominal or intrathoracic surgery. However, the protocol of PVP-I administration has not been optimized to achieve the best antitumoural efficacy. We aimed to determine the optimal concentration of PVP-I, the time of incubation and the mechanism of cell death by analysing the effect of different doses and time of administration of PVP-I on the cell viability of different mesothelioma cell lines.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic malignancy associated with poor prognosis and predicted to increase in incidence in the next decades. Patients with MPM who are not treated surgically survive at the most 12 months if they are offered the best palliative treatment [1] . A standard treatment protocol for MPM has not yet been developed, and in particular, the role of surgery including extrapleural pneumonectomy (EPP) or radical decortication, as an alternative to EPP in unfit patients, still remains controversial.
Despite attempting different multimodality therapies including surgery, MPM recurs in most patients because the mostly diffuse malignant infiltration of the surrounding tissue strictly prevents a radical resection with histologically free resection margins. Thus, other treatments such as intrathoracic perfusion chemotherapy alone or associated with hyperthermic perfusion have been applied after cytoreductive surgery with good results [2, 3] . However, such techniques are not available in all hospitals, the set-up is difficult and they may be associated with significant morbidity.
Povidone-iodine (PVP-I) or Betadine, a combination of molecular iodine and polyvinylpyrrolidone, has replaced the solution (tincture) of iodine widely used in clinical practice [4] . PVP-I has been used in hand disinfection, skin preparations and antiseptic irrigation for many years owing to the effective and wide antimicrobial activity [5] . In the last years, several studies have also addressed its use as a sclerosing agent to promote pleurodesis in recurrent malignant pleural effusion or to prevent tumour seeding at the time of abdominal or thoracic surgery [6] [7] [8] . Yet, its antitumour effects on breast cancer and MPM cells have also been demonstrated in vitro [9, 10] . The aim of the present study was to perform a comparative analysis of cell death induction by PVP-I in different cell lines of MPM focusing on dose and time of incubation dependency and the mechanism of cell death.
MATERIALS AND METHODS

Study design
To investigate the effects on proliferation and cell death of diluted PVP-I on MPM, four different cell lines (MET 5A/normal mesothelium; H2052/sarcomatoid mesothelioma; ISTMES2/epithelial mesothelioma; MSTO/biphasic mesothelioma) were incubated with increasing doses of PVP-I diluted in fresh medium (0.0001; 0.001; 0.01; 0.1; 1%) starting from a 10% PVP-I solution in distilled water, for different times (5, 10, 30, 60 min and 24 h). Cytotoxicity assay was used to examine the proliferation; flow cytometry was performed to detect the apoptotic rate; superoxide dismutase (SOD) activity was assessed functionally through a specific inhibitor to evaluate the mechanism of cell death.
The aim was to establish the time of incubation and the concentration of PVP-I that allowed a complete cell killing in order to evaluate its potential application in clinical practice.
Cell line and culture conditions
Four commercially available MPM cell lines were used in the present study: MET5A (normal mesothelium); H2052 (sarcomatoid mesothelioma); MSTO (biphasic mesothelioma), purchased from the American Type Culture Collection, and ISTMES2 (epithelial mesothelioma) from the ISTGE cell repository (www.iclc.it). All cell lines were cultured as recommended by the providers in a humidified incubator at 37°C and 5% CO 2 .
Cell treatment with povidone-iodine and MTS assay
The cytotoxicity of PVP-I in all four cell lines was determined by MTS assay (CellTiter 96 ® Aqueous One Solution Cell Proliferation Assay, Promega). Compactly, MET5A/H2052/ISTMES2/MSTO (1.0 × 10 4 cells/well) were seeded in a 96-well plate with fresh medium and incubated overnight. MTS solution was added into each well at the indicated time points (5, 10, 30, 60 min, and for 24 h) following treatment with five different concentrations of PVP-I diluted in fresh medium (0.0001; 0.001; 0.01; 0.1; 1%). As a control, cells were cultured in fresh medium added with the maximum amount of water used to vehicle the higher drug concentration (1%). Cell viability was evaluated at different time points following the manufacturer's instructions, through spectrophotometric reading at two different wavelengths (540 and 630 nm). All experiments were repeated with at least three consecutive passages.
Apoptosis analysis through flow cytometry
At the indicated incubation time, floating cells were collected together with the supernatant and adherent cells were harvested by trypsinization. Apoptosis was evaluated using Annexin V-FITC Kit (Miltenyi Biotec, Inc., USA). Cells were analysed immediately using a fluorescence activated cell sorting (FACS) flow cytometer (FACS Calibur; BD Biosciences, Heidelberg, Germany) for Annexin V-FITC and Propidium iodide (PI) staining. For each measurement, 20 000 cells were counted. Dot plots and histograms were analysed by CellQuest Pro software (BD Biosciences). Annexin V-positive cells were considered in the early stage of apoptosis (lower right quadrant); Annexin V-and PI-positive cells were considered in the late stage of apoptosis or necrotic (upper right quadrant). Annexin V-and PI-negative cells correspond to the viable cell fraction (lower left quadrant) [11] .
Analysis of superoxide dismutase activity
To study one of the probable mechanisms of PVP-I-induced cell death in tumour cells, the activity of SOD was detected with a colorimetric method [12] . MET5A, ISTMES2, MSTO and H2052 cell lines (1.5 × 10 5 cells/ml) were seeded in a 6-well plate and incubated for 24 h. Cells were then treated with five different concentrations of PVP-I (0.0001; 0.001; 0.01; 0.1; 1%) and incubated for 24 h. Next, cells were harvested and processed according to the instruction of the SOD kit (Nanjing Jiancheng Biotechnology Institute SOD kit (detect total), Nanjing, China). The activity of SOD was assessed by an ultraviolet spectrophotometer (SmartSpec 3000, Bio-Rad, Philadelphia, USA).
Statistical analysis
Data resulting from MTS and SOD activity experiments are expressed as means ± standard deviation (SD) of three independent experiments, each performed in triplicate. Statistically significant differences among the means of multiple groups were evaluated by one-way repeated-measures ANOVA, with Bonferroni post-test to compare pairs of data. The MedCalc statistical software (Version 12.3, Broekstraat 52; 9030 Mariakerke; Belgium) was used for the analysis. A P value of < 0.05 was considered statistically significant.
RESULTS
Povidone-iodine effect on mesothelioma cell growth
The effect of various incubations with different doses of PVP-I doses on mesothelioma cell growth is represented in Fig. 1 (A for MET5A, B for ISTMES2, C for MSTO and D for H2052). MET5A, ISTMES2 and MSTO cell lines presented sensitivities similar to that of PVP-I. The shortest time period necessary to observe a strong cytotoxic effect (cell viability <1%) on MET5A, ISTMES2 and MSTO cells was 10 min with a concentration of 0.1%. At a concentration of 0.1% and after 10 min of incubation, the percentage of cell viability was significantly decreased with respect to that observed after 5 min of incubation: 0.5 ± 0.1 vs 5.2 ± 0.8%, P < 0.05, respectively, for MET5A (Fig. 2A) ; 0.8 ± 0.5 vs 5.3 ± 0.5%, P < 0.05, respectively, for ISTMES2 (Fig. 2B) ; 0 vs 2.1 ± 0.1%, P < 0.05, respectively, for MSTO (Fig. 2C) . Among all three different cell lines (MET5A, ISTMES2 and MSTO), no significant differences in cell viability were found after longer incubation times at 0.1% concentration ( Conversely, 0.1% PVP-I concentration did not significantly affect the H2052 cell line which presented after 10 min of incubation a percentage of cell viability of 84 ± 0.4%. At the same concentration, the percentage of cell viability significantly decreased for longer incubation as follows: 71 ± 0.5% for 30 min (P < 0.05); 66 ± 0.2% for 60 min (P < 0.05); and 58 ± 0.9% for 24 h (P < 0.05) if compared with that observed after 5 min (88 ± 0.6%) and 10 min of incubation (84 ± 0.6%). However, these data showed that at a concentration of 0.1%, the H2052 cell line was highly resistant to PVP-I, having a survival rate above 50% also after 24 h of incubation (Fig. 3A) . At 1% concentration of PVP-I, we observed a significant decrease of survival rate in a time-dependent manner with a survival rate of 3.4 ± 0.2% (P < 0.05); of 2.2 ± 0.1% (P < 0.05) and of 0.7 ± 0.1% after 5, 10 and 30 min of incubation, respectively (Fig. 3B ).
Povidone-iodine induces cell death of mesothelioma cell lines FACS analysis revealed that PVP-I induced a dose response effect in all MPM cell lines (Fig. 4) . In particular, the percentage of dead cells proportionally increased with PVP-I concentrations and, in each group, they were mainly in the late apoptotic stage or necrosis. In agreement with the MTS results, the sensitivity of the H2052 cell line was quite different from that of the other cell lines (MET5A, ISTMES2, MSTO). For instance, at 0.1% concentration, H2052 had a percentage of viability of 58%, whereas MET5A, ISTMES2 and MSTO had a percentage of cell viability of <1%; however, H2052 also showed dead cells, which were mainly in apoptotic late phase or necrosis (33%) whereas only 6% were in early apoptotic stage.
Povidone-iodine inhibits superoxide dismutase activity in mesothelioma cell lines
The SOD assay revealed that PVP-I induced cell death due to the oxidizing effects of free iodine on SH-OH-and NH-groups of amino acids and on the double bonds of unsaturated fatty acids. Among all four cell lines, the activity of SOD was significantly inhibited at a concentration of 0.1% with respect to lower concentrations (P < 0.05). No significant difference was observed among the 0.1 and 1% groups for MET5A (Fig. 5A), ISTMES2 (Fig. 5B ) and for MSTO (Fig. 5C ) cell lines; whereas a significant difference was found between 0.1 and 1% groups for H2052 cell lines (Fig. 5D) .
DISCUSSION
PVP-I, a broad-spectrum microbicide against bacteria, virus, fungi and parasites in vitro, consists of elementary iodine bound to the carrier poly(1-vinyl-2-pyrrolidone) that enhances the solubility and provides a depot of iodine. Based on the oxidizing effects of free iodine on the NH-and SH-OH-groups of amino acids and on Figure 2 : After 10 min of incubation at a concentration of 0.1%, the percentage of cell viability was significantly decreased with respect to that observed using lower concentrations (0.0001; 0.001; 0.01%), whereas no significant difference was found for a higher concentration (1%) for MET5A (A); for ISTMES2 (B) and for MSTO (C). Among all three different cell lines, no significant differences were found after longer incubation times (D for MET5A, E for ISTMES2 and F for MSTO).
the double bonds of unsaturated fatty acids, PVP-I showed the ability of non-specifically induced cell death [12] .
Over the last years, PVP-I has also been shown to exert antineoplastic activity in vitro as well as in vivo. PVP-I induces cell death in a variety of malignant cell lines derived from breast, colon, gastric and thymic carcinoma [6] [7] [8] [9] . Clinically, many surgeons have been irrigating intraluminally with PVP-I just before resection attempting to prevent tumour recurrence after colorectal or breast cancer At 0.1% concentration, the H2052 cell line was highly resistant to PVP-I, having a survival rate of more than 50% also after 24 h of incubation (A). A significant decrease in survival rate in a time-dependent manner was observed using a higher PVP-I concentration (1%) (B). surgery [13, 14] . Others demonstrated the potential for this agent to prevent tumour implants in abdominal trocar wounds during laparoscopy for colon cancer [15] .
In the literature, only one study from Opitz et al. [10] evaluated the antiproliferative effect of PVP-I on MPM cells with promising results. The authors found that PVP-I induced a necrotic phenotype along with the production of reactive oxygen intermediates, decreased mitochondrial membrane permeability and cell death, which was inhibited by the oxygen scavanger N-acetyl cysteine.
In our in vitro experiment, we investigated the effect of PVP-I on different MPM cell lines with the first end-point to define the concentration and the incubation time to obtain an antiproliferative effect on MPM cell in vitro. The second end-point was to evaluate the PVP-I mechanism of cell death induction.
We found that MET5A, ISTMES2 and MSTO had sensitivities similar to that of PVP-I and this effect showed dependence on the concentration and time of incubation. The shortest incubation time necessary to observe a strong cytotoxic effect (<1% of cell viability) on MET5A, ISTMES2 and MSTO cells was 10 min with a concentration of 0.1%. At these levels, the percentage of cell viability was 0.5, 0.99 and 0.1% for MET5A, ISTMES2 and MSTO, respectively. Similar results were obtained for longer incubations (30, 60 min and 24 h). No morphological differences were found at different times of incubation. Conversely, the H2052 cell lines resulted to be more resistant than MET5A, ISTMES2 and MSTO cell lines; to obtain a cell viability of 0.7%, a longer incubation (30 min or more) was required with a higher PVP-I concentration (1%). Our data are in agreement with those of Opitz et al. [10] , who found that the cytotoxic effect obtained with PVP-I on MPM for different incubation times (7.5 min, 24 and 48 h) were comparable. Conversely, higher concentrations of PVP-I (2% or more) were reported to kill human colonic carcinoma cells [12] .
The cell death fractions of MET5A, MSTO, ISTMES2 and H2025 treated with PVP-I were also measured by flow cytometry. Our results showed that PVP-I can induce cell death in a dosedependent manner. In agreement with the MTS results, H2052 cells were more resistant than the other cell lines to the cytotoxic effect of PVP-I. However, in all cell lines studied, the reduction of cell viability was mirrored by the exclusive enhancement of late phase apoptosis or necrosis (upper right quadrant) without any significant effect on early apoptosis (lower right quadrant), suggesting that PVP-I inhibited MPM cell growth via necrosis. According to our results, similar findings were obtained in human embryonic fibroblasts [6] and in the study by Opitz et al. [10] , who showed that the necrosis induced by PVP-I was due to a high production of reactive oxygen intermediates and low mitochondrial membrane permeability. Our findings seem striking in that mesothelioma cell lines in vivo and in vitro have been shown to be exquisitely resistant to apoptosis from a number of conventional stimuli, including hydrogen peroxide, asbestos fibres and calcium ionophore [16] . Yet, the necrosis of MPM cells induced by PVP-I could have important consequences in the clinical practice. Unlike apoptosis, necrosis induces an inflammatory response, which may recruit immune cells to the tumour site and therefore enhance the antitumoural response [17, 18] .
The necrosis induced by PVP-I might be due to the inhibition of SOD activity. Consistently, we observed a dose-dependent inhibition of SOD activity in all cell lines, which was significant at both 0.1 and 1% PVP-I concentrations. Calcium and reactive oxygen species are key players during the propagation and execution phases of necrotic cell death, directly or indirectly provoking damage to proteins, lipids and DNA [19] . Thus, by clearing the superoxide anion, which promotes the cell generating oxidative stress, SOD activity counteracts damage to the cells and the consequent necrosis induction [20] .
According to our results, PVP-I might be used in the future as local treatment of MPM after surgery. Considering the difficulty to have free margins from tumour after radical resection, continuous local infusion of intrapleural chemotherapy alone or in association with hyperthermic infusion has been utilized in the treatment of abdominal and thoracic mesothelioma in several studies. However, the technique is cumbersome and associated with significant morbidity. Perfusion (hyperthermic) chemotherapy requires inflow and outflow catheters, a pump system, temperature sensors, heat exchanger, filters and roller pump [8] . The set-up of chemotherapy is difficult and adds significant time to the duration of the procedure, and when performed as part of EPP, the mean operative time was above 6 h. Our results showed that PVP-I is potentially cytotoxic, and thus, theoretically the lavage of pleural cavity after cytoreductive surgery may help to clean the margin of resection from tumour cells reducing the recurrence of cancer. In contrast to intrapleural chemotherapy, which adds considerable complexity and time to cytoreductive surgery, PVP-I pleural lavage is simple, cost-effective, and adds little additional time to the procedure. The use of PVP-I should be considered when an epithelioid or biphasic mesothelioma is operated because such histological types resulted to be sensible to the antitumour properties of PVP-I with respect to the sarcomatoid MPM.
To have a valid effect, it is reasonable to lavage the pleural cavity with a PVP-I concentration not less than 0.1% for 10 min. Yet, our results on SOD activity suggested that the cytotoxic effect of PVP-I might be caused by the oxidizing effects of its free iodine. This is a key finding of our paper. In fact, as the free iodine level is dependent on the concentration of solution, diluted solutions of PVP-I have smaller iodine reservoirs and therefore less killing capacity. In addition, organic materials including proteins, red blood cells and free haemoglobin were found to inhibit the tumouricidal activity of PVP-I [9] ; thus, the removal of organic material might be beneficial in surgical practice to achieve killing of tumour cell without increasing PVP-I concentration.
Despite safe, PVP-I presented an aspecific cytotoxic effect considering that inhibited the proliferation not only of malignant cells but also of the normal mesothelial cells (MET5A). This, however, could be of little importance because MPM usually interests all mesothelium and a radical resection of pleura is always performed with a curative intent. However, PVP-I might be toxic for other tissues. Wagenfeld et al. [21] reported three cases of bilateral severe loss of vision after thoracoscopic surgery involving resection of parts of one lung and instillation of 200-500 ml of Jodobac, a 10% PVP-I solution, into the thoracic cavity for disinfection and to cause scarring of the pleura for prophylaxis against pneumothorax. Thus, we advice to use a 0.1% PVP-I concentration for 10 min. This achieves a massive cytotoxic effect and presumably lacks significant toxicity considering that it is 110-fold lower than the concentration usually used for its antibiotic effect.
Since the risk of wound and/or trocar-site recurrence in patients undergoing cytoreductive surgery or having a biopsy done thoracoscopically for MPM is a well-known evidence, in theory the application of PVP-I at these levels could prevent recurrence through clearance of tumour cells.
Study limitation
Our study provided a theoretical basis on the antineoplastic activity of PVP-I on MPM cell lines at preclinical level. However, since commercially available MPM cell lines might have different responses compared with human MPMs, it remains to be assessed whether the data observed in vitro are reproducible in vivo, in terms of dose and incubation response, and can be effectively translated to the clinical practice. Thus, further studies need to be undertaken to assess the effect of PVP-I on MPM experimental animal models before its potential use in human clinical trials. In addition, in the present study, we used normal mesothelium (MET5A cell lines) as control. PVP-I reduced the proliferation of normal mesothelium as well as that of MPM cell lines (ISTMES2, and MSTO). In view of its potential clinical application, that may have little importance because MPM strictly interests all mesothelium and it is hard to differentiate normal mesothelium from cancer. In addition, the concentration of Betadine inducing an antitumoural effect was 0.1%, and was thus 110-fold significantly lower than the concentration usually used for its antiseptic effect (10%). However, as reported above, the end-point of this study was to determine the antineoplastic activity of Betadine in vitro providing the preclinical framework for the possible use of Betadine in the clinical setting. Obviously, future experiments aim to analyse in vivo the activity of Betadine and its possible side effect profiles in order to verify the possibility for an effective translation to the clinical practice and to define the final therapeutic dose.
CONCLUSION
Our data confirmed that low doses and short exposures to PVP-I have antiproliferative effects also on MPM cells via inducing cell death in a dose-dependent manner. H2052 cells, derived from the most aggressive sarcomatoid histotype, were more resistant than the other cell lines. Inhibition of SOD activity by PVP-I seems to underlie the mechanism of cell death. However, our in vitro data should be corroborated by in vivo studies in animal models of mesothelioma before recommending the intraoperative pleural lavage with PVP-I as adjuvant treatment to surgery for MPM.
